Metagenomi Therapeutics (MGX) Q3 2026 earnings summary

Executive summary

• FDA cleared the MGX-001 IND in November 2026 for a Phase 1/2 hemophilia A trial; the one-time treatment is designed for durable endogenous FVIII production through site-specific integration at the albumin locus.

• Preclinical studies showed physiologic-range FVIII activity and no detectable off-target editing; NHP results also showed activity durability, alongside variability that prompted further studies and consideration of alternative FVIII constructs.

Financial highlights

• Q3 collaboration revenue was $2.184M vs. $8.659M YoY; 9M revenue was $3.175M vs. $21.299M.

• Q3 operating expenses were $24.410M vs. $31.498M; operating loss was $22.226M vs. $22.839M.

• Q3 net loss was $21.126M vs. $20.393M; 9M net loss was $71.667M vs. $65.340M.

• Q3 R&D expense was $17.532M vs. $25.283M; 9M R&D was $59.344M vs. $72.932M.

• Q3 G&A was $6.878M vs. $6.215M, including $1.194M of net litigation settlement expense.

Outlook and guidance

• $101.7M of cash, cash equivalents and available-for-sale securities at September 30, 2026 was expected to fund the current operating plan for at least 12 months from financial-statement issuance; runway was also projected into 2028.

• INTEGR8 is planned as a global, multicenter, open-label Phase 1/2 dose-escalation and expansion study in adults with moderately severe to severe hemophilia A; initiation is targeted for H1 2027, with initial data expected in H2 2027.

• R&D and G&A expenses are expected to increase as programs advance; additional funding is expected before product revenue.